vipadenant
Small moleculeexperimental
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2006 (NCT00451815)
Timeline
Indications
Mechanism of action
- Bradykinin B1 receptorANTAGONIST
BDKRB1 antagonist
- Adenosine A2a receptorANTAGONIST
ADORA2A antagonist
Decvelopment of compound against Parkinson's discontinued but Vernalis has outlicensed the compound to Redox Therapies for use in immuno-oncology. Also high potency at ADORA2B, ADORA1A and ADORA3
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(Cn2nnc3c(-c4ccco4)nc(N)nc32)ccc1N- Mol. weight
- 321.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL447664 ↗
- ChEMBLCHEMBL3545386 ↗
Also known as
- 3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3h-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine
- bi113823
- bi 113823
- biib014
- biib014
- biib014
- biib-014
- biib-014
- v2006
- v2006
- v 2006
- v-2006
- v2006 cpd
- vipadenant
- vipadenant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01207973 | Phase 1 | Sep 1, 2010 | Boehringer Ingelheim |
| NCT01189175 | Phase 1 | Aug 1, 2010 | Boehringer Ingelheim |
| NCT02259972 | Phase 1 | Jan 1, 2010 | Boehringer Ingelheim |
| NCT01035515 | Phase 1 | Dec 1, 2009 | Biogen |
| NCT01017666 | Phase 1 | Nov 1, 2009 | Biogen |
| NCT00531193 | Phase 1 | Sep 1, 2007 | Biogen |
| NCT00442780 | Phase 2 | Aug 1, 2007 | Biogen |
| NCT00438607 | Phase 2 | Apr 1, 2007 | Biogen |
| NCT00451815 | Phase 2 | Jan 31, 2006 | Biogen |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 6 | 6 | 2 | 2006 |
| Boehringer Ingelheim | For profit | 3 | 3 | 1 | 2010 |
2 organizations
Page 1 / 1